KALV - CIK 0001348911
KalVista Pharmaceuticals, Inc. (KALV) reported revenue of $50.00M for fiscal year 2024, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2024 | $50.00M | +294.0% |
| FY 2020 | $12.69M | -21.3% |
| FY 2019 | $16.13M | +92.1% |
| FY 2018 | $8.39M | +458.1% |
| FY 2017 | $1.50M | -29.5% |
| FY 2016 | $2.13M | - |
KalVista Pharmaceuticals, Inc. (KALV) reported revenue of $50.00M for fiscal year 2024, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2024, KalVista Pharmaceuticals, Inc.'s revenue grew from $2.13M to $50.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.